Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Oral PF-06700841 containing 14C microtracer
PF-06700841 containing 14C microtracer · 1 trial · 1 indication
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
| Arm | Type | Description |
|---|---|---|
| 2-period, fixed sequence | EXPERIMENTAL | fixed sequence with 2 treatment period |
| Name | Type | Description |
|---|---|---|
| Oral PF-06700841 containing 14C microtracer | DRUG | Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period |
| Oral unlabeled PF-06700841 | DRUG | 60 mg unlabeled PF-06700841 oral dose in 2nd period |
| IV 14C-labeled PF-06700841 | DRUG | 30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period |
Exclusion Criteria: * Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection). * Total 14C radioactivity measured in plasma exceeding 11 mBq/mL * History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test * Use of ...
PF-06700841 containing 14C microtracer is an oral small molecule developed by Pfizer, Inc. (NYSE: PFE). It combines an unlabeled dose of PF-06700841 with a carbon-14 labeled microdose, a technique used in early clinical research to study how a drug is absorbed, distributed, metabolized, and excreted in the body.
Pfizer, Inc. (ticker PFE) is the developer of PF-06700841 containing 14C microtracer. The compound was studied in a single Phase 1 trial conducted by Pfizer, and no other sponsors or partners are associated with this microtracer formulation.
PF-06700841 containing 14C microtracer is in Phase 1 development. It is an investigational agent and has not been approved by the FDA. The only recorded trial, NCT03770039, is a completed Phase 1 study, and no active trials of this microtracer formulation are ongoing.
PF-06700841 containing 14C microtracer was evaluated in one completed Phase 1 trial, NCT03770039, titled Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects. The study enrolled 6 healthy male volunteers aged 18 years and older in the Netherlands.
Yes. PF-06700841 containing 14C microtracer is also known as oral PF-06700841 containing 14C microtracer. Both names refer to the same Pfizer small molecule formulation that pairs an unlabeled dose with a carbon-14 labeled microdose for human absorption, metabolism, and excretion research.
NCT03770039 was an uncontrolled, open-label Phase 1 study, not randomized and not double blinded. It enrolled 6 healthy male subjects in the Netherlands and has been completed. The trial used a single unlabeled dose together with a 14C-labeled microdose of PF-06700841.